PO.CTP01.03 · 进行中的临床试验
OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS / BRAF wild-type colorectal cancer
该海报暂无可访问的完整资料
AACR 官方页面 ↗
作者与单位
摘要 Abstract
Background: Among patients with metastatic colorectal cancer (mCRC), approximately 50% are wild-type for KRAS , NRAS , and BRAF ( RAS/BRAF WT) without actionable genomic alterations. Standard first-line therapy for RAS/ B RAF WT mCRC is 5-FU-based doublet chemotherapy (FOLFOX or FOLFIRI) plus anti-EGFR or anti-VEGF therapy. The choice of second-line treatment is dependent on first-line treatment (eg, oxaliplatin-based chemotherapy in the first-line necessitates irinotecan-based in the second-line, and vice versa). Known resistance mechanisms to anti-EGFR therapy are MET alterations, with MET amplification occurring in 5%-23% of EGFR-resistant mCRC and increasing in prevalence over subsequent lines of therapy. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity and is FDA-approved for 4 indications in EGFR -mutated advanced non-small cell lung cancer. In the phase 1b/2 OrigAMI-1 study (NCT05379595), amivantamab plus FOLFIRI demonstrated promising antitumor activity, independent of line of therapy, in participants (pts) with RAS / BRAF WT mCRC without prior anti-EGFR exposure (Pietrantonio ESMO 2024). The objective of this phase 3 randomized study is to assess the efficacy of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI, as second-line therapy for pts with recurrent RAS / BRAF WT mCRC.
Methods: The global OrigAMI-3 study (NCT06750094) is planned to open in 230 sites in 25 countries. Eligible pts will be WT for KRAS , NRAS , and BRAF , have recurrent unresectable or mCRC, and must have had disease progression on one prior line of systemic therapy for metastatic disease (prior regimen must be fluoropyrimidine-based and oxaliplatin-based therapy). Pts with treated, stable, and asymptomatic brain metastases are allowed. Key exclusion criteria include known dMMR/MSI-H status without prior immunotherapy, HER2-positive or amplified tumor, and prior exposure to irinotecan or agents targeting EGFR or MET. Approximately 700 pts will be randomly assigned 1:1 to receive subcutaneous amivantamab (co-formulated with recombinant human hyaluronidase [rHuPH20]) plus FOLFIRI vs intravenous cetuximab or bevacizumab (investigator's choice, per local guidelines) plus FOLFIRI. Randomization will be stratified by choice of cetuximab or bevacizumab, primary tumor location (left vs right-sided), duration of first-line therapy (<6 months or ≥6 months), and prior anti-VEGF therapy (yes or no). The dual primary endpoints will be progression-free survival by blinded independent central review and overall survival. Secondary endpoints include objective response rate, duration of response, and patient-reported outcomes. Safety assessments will include monitoring adverse events and laboratory abnormalities.
利益披露 Disclosure
J. Hecht,
Astellas, Bristol Myers Squibb, Taiho Pharmaceutical, BeiGene, IGM Biosciences, Novartis, Galvanize, Exelixis, and Deciphera Other, consulting fees.
Scripps, American Gastroenterological Association, MJH Life Sciences, and Research to Practice Other, consulting fees.
Triumvira, Actym, and MBQ Pharma Stock.
E. Élez,
Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cureteq AG, Janssen, Lilly, Medscape, Merck, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Repare Therapeutics Other, honoraria.
RIN Institute, Roche, Sanofi-Aventis, Seagen, Servier, and Takeda Other, honoraria.
Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cureteq AG, Janssen, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Repare Therapeutics, RIN Institute, Roche, Sanofi-Aventis Other, consulting or advisory role.
Seagen, Servier, and Takeda Other, consulting or advisory role.
AbbVie, Amgen, Array BioPharma, AstraZeneca, Bayer, BeiGene, Bioncotech, BioNTech RNA Pharmaceuticals GMBH, BioNTech Small Molecules GMBH, Boehringer Ingelheim, Boehringer Ingelheim Spain ).
Bristol Myers Squibb, Celgene, Daiichi Sankyo, Debiopharm, Genentech, Gercor, HalioDX SAS, Roche, Hutchison MediPharma, Iovance Biotherapeutics, Janssen Research & Development, Janssen-Cilag SA ).
MedImmune, Menarini, Merck, Merck Sharp & Dohme (Spain) ).
Merus NV, Mirati Therapeutics, Nouscom SRL, Novartis, Novartis Farmacéutica SA, Pfizer, PharmaMar, Pierre Fabre, PledPharma, Redx Pharma, Roche, Sanofi, Scandion Oncology, Seagen, Servier, Sotio, Tai ).
Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cureteq AG, Janssen, Lilly, Medscape, Merck, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Repare Therapeutics Travel.
RIN Institute, Roche, Sanofi, Seagen, Servier, and Takeda Travel.
C. Eng,
Elevar Therapeutics (institution), Elevation Oncology, General Electric, GSK, Gritstone bio (institution), Hutchison MediPharma (institution), Janssen Oncology, Merck (institution), Merck Serono Other, consulting or advisory role.
Natera, Pfizer (institution), and Seagen Other, consulting or advisory role.
P. Gibbs,
Amgen, Merck, MSD Oncology, Roche, SERVIER Other, honoraria.
Amgen, Bayer, BMS, Sanofi, Merck Serono, Pierre Fabre, Roche, Roche Molecular Diagnostics, Servier, Takeda ).
Haystack Oncology Other, consulting or advisory.
J. Seligmann,
GlaxoSmithKline, Merck Serono, Pierre Fabre, SERVIER, Takeda Science Foundation Other, honoraria.
Elevation Oncology, GlaxoSmithKline, Jazz Pharma, Merck Serono, Sanofi, Takeda Other, Consulting or Advisory.
GlaxoSmithKline, Merck Serono, Pierre Fabre ).
R. Xu,
Astellas, AstraZeneca, BeiGene, CPPC, Hengrui Pharm, Hutchison MediPharma, Innovent Biologics, Junshi Pharma, Keymed Bioscience, Merck Serono, MSD, QiLu Pharma, Roche Other, Consulting or advisory.
K. Yamaguchi,
BMS Japan, Daiichi Sankyo Other, Consulting or advisory.
Ono Pharma, Taiho Pharma, Daiichi Sankyo, Lilly, Gilead Sciences, Yakult Honsha, Chugai Pharma, Boehringer Ingelheim, Eisai, MSD Oncology, Sanofi, BMS ).
Chugai Pharma, BMS Japan, Takeda, Taiho Pharma, Lilly, Ono Pharma, Daiichi Sankyo, Merck Other, Speakers Bureau.
J. Wang, None.
H. Teng,
MSD Other, Consulting or Advisory, Speakers Bureau.
Merck Sharp & Dohme LLC ).
L. Trani,
Johnson & Johnson Employment, Stock.
H. Wortman-Vayn,
Johnson & Johnson Employment, Stock.
Z. Jiang,
Johnson & Johnson Employment, Stock.
B. Diorio,
Johnson & Johnson Employment, Stock.
P. Lorenzini,
Johnson & Johnson Employment, Stock.
C. Baudelet,
Johnson & Johnson Employment, Stock.
S. Sethi,
Johnson & Johnson Employment, Stock.
M. Baig,
Johnson & Johnson Employment, Stock.
C. Cremolini,
Roche, Amgen, Bayer, Servier, MSD, Merck, Pierre Fabre Other, Honoraria.
Roche, Bayer, Amgen, MSD, Pierre Fabre, Nordic Bioscience Other, Consulting or advisory.
Servier, Merck, Pierre Fabre Other, Speakers Bureau.
Merck, Bayer, Roche, Servier ).